- Targets ARDS with Mesenchymal Stem Cells (MSCs).
- MSCs are quick to produce, can scale easily.
- Favorable safety profile proven in historical use.
- Clinical trials planned pending FDA approval
“Despite the challenges presented by COVID-19, we are in the midst of an exciting time for Citius.
We’re hard at work on a potentially groundbreaking treatment for ARDS associated with COVID-19, and our core therapies are making steady progress through their respective clinical development timelines”Myron Holubiak, CEO – Citius Pharma
In early April, Citius Pharmaceuticals signed an agreement with Novellus to fight COVID-19 related ARDS with stem cells.
Novellus’ cellular process relies on its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) reprogramming process to create a master cell bank of induced pluripotent stem cells (iPSCs). Their patented RiboCell™ technology uses non-immunogenic mRNA molecules to efficiently create pluripotent stem cells rapidly and without the use of viruses or DNA-based vectors.
The iPSCs create mesenchymal stem cells (MSCs) that, due to their multi-potent nature and their ability to secrete multiple paracrine factors, such as anti-inflammatory cytokines, can potentially treat the major abnormalities that underlie ARDS. While the immunomodulatory properties of MSCs have been well characterized, clinical results in ARDS are only now being investigated.
The cellular processing technology used by Novellus provides a virtually unlimited supply of MSCs (called NC-MSCs) that are allogeneic (i.e., “off-the-shelf”).
NC-MSCs are derived from a new and improved source, are quick to produce, can scale easily, can be transported and delivered easily, and are especially potent. Furthermore, MSCs, in general, have a favorable safety profile from their history of use in other indications.